)
Matthew Beton
Director (Process Development),
Tr1X
Matt is the current Director of Process Development at Tr1X – a company developing a novel class of off-the-shelf reguatory T-cell based products to cure autoimmune and inflammatory diseases. Matt has over a decade of experience in C> process development and manufacturing, with a successful track record of helping small to midsize Biotechs advance their cell therapy programs starting from early pre clinical development to Phase I/II clinical trials, and on to BLA filing. Prior to Tr1X, Matt served as the Associate Director of MSAT for Poseida Therapeutics, where he oversaw late stage process development and MSAT for the company’s leading allogeneic cell therapy assets, P-BCMA-ALLO1 and P-MUC1C-ALLO1.